Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation

Figure 4 Upregulation of tumor protein p53, murine double minute 2, murine double minute 4, and cyclin-dependent kinase 9 correlates with poor prognosis in hepatocellular carcinoma patients. A: The expression of murine double minute 2 (MDM2), phosphorylated MDM2, MDM4, phosphorylated MDM4, cell division cycle 7 (CDC7), and cyclin-dependent kinase 9 (CDK9) in clinical hepatocellular carcinoma (HCC) specimens was assessed using immunohistochemical analysis; B: The mRNA levels of tumor protein p53, MDM2, MDM4, CDC7, CDK9, and B-rapidly accelerated fibrosarcoma proto-oncogene serine/threonine kinase were analyzed in HCC patients using datasets from The Cancer Genome Atlas and Gene Expression Omnibus repositories; C: Kaplan-Meier survival analysis were performed based on the expression of tumor protein p53, MDM2, MDM4, CDC7, CDK9, and B-rapidly accelerated fibrosarcoma proto-oncogene serine/threonine kinase and their regulatory proteins, showing a significant correlation with overall survival in HCC patients. Data are presented as mean ± SD. ^bP < 0.01, ^dP < 0.0001, ns: P > 0.05. CDC7: Cell division cycle 7; CDK9: Cyclin-dependent kinase 9; MDM2: Murine double minute 2; TP53: Tumor protein p53; MDM4: Murine double minute 4; BRAF: B-rapidly accelerated fibrosarcoma proto-oncogene serine/threonine kinase.